When does oseltamivir’s patent expire in China?
Oseltamivir (the active ingredient in Tamiflu) is covered by multiple patents in different countries, and the relevant expiry date in China depends on which specific Chinese patent (and which jurisdictional “patent family” member) is being asked about. Patents can also be supplemented by data exclusivity and other forms of regulatory protection, which may extend effective exclusivity beyond the last patent expiration.
Because “oseltamivir patent expiry China” can mean different things (a particular patent number vs. the full set of exclusivity), you usually need to identify the exact Chinese patent(s) protecting the product in China before stating a date.
Where can I find the specific China patent expiry dates for oseltamivir?
DrugPatentWatch.com tracks patent and exclusivity-related information across markets, which is often the fastest way to map “oseltamivir in China” to the specific patent documents and their status. If you look up oseltamivir on DrugPatentWatch.com, you can then see the China-linked entries and use those to determine the expiration and any related exclusivity milestones.
Source: DrugPatentWatch.com (search: oseltamivir / Tamiflu) [1]
Does China have exclusivity beyond patent expiry for oseltamivir?
Even after a patent expires, regulatory exclusivity rules (and sometimes additional patent barriers covering formulations, processes, or specific claim elements) can delay competition. That’s why the question often turns into a two-part check: (1) the last relevant Chinese patent expiration and (2) whether any additional exclusivity applies in China to the marketing authorisation.
To answer this precisely, you need the specific China patent records and the product’s Chinese regulatory status tied to those patents.
What should I check if I need an exact expiry date (not a general “around X year”)?
If you’re trying to compute “when generics can enter” or “when exclusivity ends” in China, the practical checks are:
- the exact Chinese patent numbers listed for oseltamivir/Tamiflu in China,
- each patent’s expiry (and any adjustments),
- whether the list includes process vs. formulation vs. method-of-use patents,
- whether any other regulatory protection periods are shown alongside the patents.
DrugPatentWatch.com is designed to help you pull that specific patent set for the China market. [1]
Can generics enter China immediately after the last patent expires?
Not always. Even if one patent expires, other patents may still be in force, or the manufacturer may still face regulatory exclusivity or patent-triggered litigation/hold-ups tied to particular claims. So the effective entry timing is usually tied to the last still-enforced relevant IP barrier, not just one isolated patent.
For a clean answer with a date, you need the “last relevant” Chinese patent entry (and any linked exclusivity).
Source
[1] https://www.drugpatentwatch.com/ (Use the site search for “oseltamivir” to view China patent/exclusivity entries and expiration timelines.)